Automatic Genetic Risk Assessment Calculation Using Breast Cancer Family History Data from the EHR compared to Self-Report.

Specific PHGKB|Cancer|PHGKB

Breast Cancer Genomics

- Cancer PHGKB -

What's New

Last Posted: Mar 07, 2019

---

• Automatic Genetic Risk Assessment Calculation Using Breast Cancer Family History Data from the EHR compared to Self-Report.  
  Sin Margaret et al. AMIA ... Annual Symposium proceedings. AMIA Symposium 2018 2018970-978
• Clinical significance of blood-based miRNAs as diagnostic and prognostic nucleic acid markers in breast cancer: Comparative to conventional tumor markers.  
  Swellam Menha et al. Journal of cellular biochemistry 2019 Mar
• CYP2D6-inhibiting medication use and inherited CYP2D6 variation in relation to adverse breast cancer outcomes after tamoxifen therapy.  
  Mayer Sophie E et al. Cancer causes & control : CCC 2019 Jan 30(1) 103-112
• Genetic counseling, genetic testing, and risk perceptions for breast and colorectal cancer: Results from the 2015 National Health Interview Survey.  
  Turbitt Erin et al. Preventive medicine 2019 Feb 12312-19
• Potential value of circulatory microRNA122 gene expression as a prognostic and metastatic prediction marker for breast cancer.  
  Saleh Amany A et al. Molecular biology reports 2019 Mar
• RILA blood biomarker as a predictor of radiation-induced sarcoma in a matched cohort study.  
  Mirjolet C et al. EBioMedicine 2019 Feb
• "Decoding hereditary breast cancer" benefits and questions from multigene panel testing.  
  Colas Chrystelle et al. Breast (Edinburgh, Scotland) 2019 Jan 4529-35
• Genetic Testing to Guide Risk-Stratified Screens for Breast Cancer.  
  Willoughby Ava et al. Journal of personalized medicine 2019 Mar 9(1)
• Hereditary Breast Cancer: What You Can – and Can't – Learn from Genetic Testing, 
  by Dr. Constance M Chen, PRWeb, March 4, 2019
• Response to Roberts et al. 2018: cohort ascertainment and methods of analysis impact the association between cancer and genetic predisposition - the tale of breast cancer risk and Lynch syndrome genes MSH6/PMS2.  
  Wang Xia et al. Genetics in medicine : official journal of the American College of Medical Genetics 2019 Feb
• [Applying decision trees to establish risk rating model of breast cancer incidence based on non-genetic factors among Southwest China females].  
  Li Q et al. Zhonghua zhong liu za zhi [Chinese journal of oncology] 2018 Nov 40(11) 872-877
• Clinical criteria revision for hereditary lobular breast cancer associated with E-cadherin germline mutations.  
  Corso Giovanni et al. Personalized medicine 2018 15(3) 153-155
• CYP2C19*2 and CYP2C19*17 variants and effect of tamoxifen on breast cancer recurrence: Analysis of the International Tamoxifen Pharmacogenomics Consortium dataset.  
  Damkier Per et al. Scientific reports 2017 7(1) 7727
• Genetic Modifiers of the Breast Tumor Microenvironment.  
  Flister Michael J et al. Trends in cancer 2018 4(6) 429-444
• Identification of a five-lncRNA signature for predicting the risk of tumor recurrence in patients with breast cancer.  
  Li Jie et al. International journal of cancer 2018 143(9) 2150-2160